SeaSun Biomaterials announced on the 2nd that it has recently signed a business agreement with GSBIO, a Chinese automation equipment company, to establish a joint venture to advance into China in the in vitro diagnostic field.

When a joint venture is established, GSBIO will be in charge of building an automated platform for in vitro diagnostic products, clinical trials related to marketing, and sales and distribution. SeaSun Biomaterials will be in charge of product production and approval process.

SeaSun Biomaterials' diagnostic product line consists of three platforms: obstetrics and gynecology, cancer, and personal genomes. Among them, SeaSun Biomaterials supplies six products approved by the Ministry of Food and Drug Safety to the third-party inspection organization, which is a specialized consignment organization for diagnostic tests. Enters product production.

SeaSun Biomaterials 'U-TOP MSI Detection Kit', which is necessary for early diagnosis of colorectal and stomach cancer and precise medical treatment, and'Patio NIPT Detection Kit', a prenatal fetal genetic test. It is planning to target the Chinese market with its main product.

Park Hee-kyung, CEO of SeaSun Biomaterials, said, "The establishment of a joint venture in China has laid a bridgehead for entry into China. We can aim for early market entry through rapid clinical trials and approval procedures in China. By sharing the bio, we can minimize technology leakage and stably accumulate know-how for market development.”

He then said, "We are discussing contracts with Europe, the United States, and East Asia to enter the market."